Role of Trans‐Cystic Stenting in Management of Choledocholithiasis During Cholecystectomy
ANZ Journal of Surgery · 2026-05 · 96 (5) · 1234-1238
DOI: 10.1111/ans.70586 ↗At a glance
Journal article in ANZ Journal of Surgery, published online on 2026-03-17. Written by Matthew Marshall-Webb and 4 co-authors. Institution: Department of UGI and HPB Surgery, Box Hill Hospital, Box Hill, Victoria, Australia. Major MEDLINE topics: Choledocholithiasis, Stents, Cholangiopancreatography, Endoscopic Retrograde, Cholecystectomy, Laparoscopic. 18 references.
Abstract (original language)
Introduction
Choledocholithiasis detected during laparoscopic cholecystectomy is common. There is no consensus for the best management in this context. Trans‐cystic biliary stent insertion is a well described but less commonly used method for managing choledocholithiasis with the gallbladder in situ.
Methods
Retrospective study including all patients undergoing trans‐cystic biliary stenting followed by ERCP at Box Hill Hospital, from 2021 to 2024. Outcomes compared to control cohort of native ERCP for choledocholithiasis at the same institution. The primary outcome was post‐ERCP pancreatitis.
Results
Trans‐cystic stenting was attempted in 49 patients. 45 (92%) were successful. The median age was 52 years, 73.4% were female, and 67% admitted emergently. No episodes of post‐ERCP pancreatitis occurred when the trans‐cystic stent was in position at ERCP, compared with 5% in the control cohort. Biliary cannulation rate was 97% if a stent was present, compared with 91% in the control cohort. 20% of stents had migrated by the time of ERCP. One patient developed pancreatitis post failed trans‐cystic stent attempt. No other complications were recorded. The median length of stay (LOS) was 5.0 days. A 40% of patients were discharged prior to ERCP, resulting in a shorter median LOS: 4.0 versus 6.0 days ( p = 0.014). No statistical differences were detected between variables for unsuccessful stenting, stent mis‐deployment, or stent migration.
Conclusion
Trans‐cystic stenting resulted in a low rate of post‐ERCP pancreatitis and a high rate of biliary cannulation. It can be safely implemented by general surgeons and may result in a reduced length of stay.
Subjects
MeSH terms (MEDLINE)
Authors and institutions
- Department of UGI and HPB Surgery, Box Hill Hospital, Box Hill, Victoria, Australia.
- Department of Surgery, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand.
ORCID profiles: Matthew Marshall-Webb, Adrian Fox
Cite
APA
Marshall-Webb, M., Smart, G., Chao, P., Hassen, S., & Fox, A. (2026). Role of Trans‐Cystic Stenting in Management of Choledocholithiasis During Cholecystectomy. ANZ Journal of Surgery, 96(5), 1234-1238. https://doi.org/10.1111/ans.70586
Vancouver
Marshall-Webb M, Smart G, Chao P, Hassen S, Fox A. Role of Trans‐Cystic Stenting in Management of Choledocholithiasis During Cholecystectomy. ANZ Journal of Surgery. 2026;96(5):1234-1238. doi:10.1111/ans.70586
BibTeX
@article{MarshallWebb2026,
author = {Marshall-Webb, Matthew and Smart, Gili and Chao, Phillip and Hassen, Sayed and Fox, Adrian},
title = {Role of Trans‐Cystic Stenting in Management of Choledocholithiasis During Cholecystectomy},
journal = {ANZ Journal of Surgery},
year = {2026},
volume = {96},
number = {5},
pages = {1234--1238},
doi = {10.1111/ans.70586}
}
EUVIMED